105496-31-9

Usage

Uses

Used in Pharmaceutical Industry:
N-FMOC-ETHANOLAMINE is used as a protecting group for amino acids during peptide synthesis. The Fmoc group provides a stable and easily removable protection for the amino group, allowing for the stepwise assembly of peptides without racemization or side reactions.
Used in Chemical Synthesis:
N-FMOC-ETHANOLAMINE is used as a building block in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals. Its reactivity and compatibility with various reaction conditions make it a valuable intermediate in the development of new molecules.
Used in Material Science:
N-FMOC-ETHANOLAMINE is used in the preparation of amphiphilic lactosides, which are important components in the development of self-assembling materials and drug delivery systems. These lactosides can form micelles, liposomes, or other nanostructures with potential applications in targeted drug delivery and imaging.

InChI:InChI=1/C17H17NO3/c19-10-9-18-17(20)21-11-16-14-7-3-1-5-12(14)13-6-2-4-8-15(13)16/h1-8,16,19H,9-11H2,(H,18,20)

Upstream product

• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 141-43-5 ethanolamine 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 29022-11-5 N-(fluoren-9-ylmethoxycarbonyl)glycine 
• 2002-24-6 2-amino-ethanol hydrochloride 

Downstream Products

• 153765-09-4 9-fluorenylmethoxycarbonyl-O-(4,4'-dimethoxytrityl)ethanolamine 
• 156939-62-7 (9H-fluoren-9-yl)methyl(2-oxoethyl)carbamate 
• 340187-12-4 (9H-fluoren-9-yl)methyl (2-bromoethyl)carbamate 
• 1386972-45-7 2'-(9H-fluoren-9-yl)methoxycarbonylaminoethyl-3-O-acetyl-2-azido-4-O-benzyl-6-O-(tert-butyldiphenylsilyl)-2-deoxy-α-D-glucopyranoside 

Relevant academic research and scientific papers

A multifunctional anomeric linker for the chemoenzymatic synthesis of complex oligosaccharides

A new anomeric linker has been developed that facilitates the purification of glycans prepared by chemoenzymatic approaches and can readily give compounds that are appropriately modified for microarray development or glycan derivatives with a free reducing end that are needed as standards for the development of analytical protocols.

A releasable disulfide carbonate linker for molecular hydrogelations

We used a releasable disulfide carbonate linker to construct precursors of gelators and form stable gels.

Repetitive solid-phase synthesis of polyamines

A repetitive solid-phase method for the synthesis of polyamines is described. Primary amino groups attached to a crosslinked polystyrene resin are monoalkylated by acid labile, benzhydryl-based alkyl chlorides. Reductive alkylation of the resulting secondary amino group by Fmoc-protected aminoaldehydes gives a N-benzhydryl polyamine backbone. Treatment of the resin with trifluoroacetic acid cleaves both the benzhydryl protective group and the polyamine derivative from the resin. By using benzhydryl protective groups with different acid stability, unbranched, branched and partly branched polyamines are synthesized.

Design and synthesis of a novel peptidomimetic inhibitor of HIV-1 Tat-TAR interactions: Squaryldiamide as a new potential bioisostere of unsubstituted guanidine

By performing RNA-targeted structure-activity relationship studies, we discovered a novel peptidomimetic containing squaryldiamide as a potential bioisostere replacement for guanidine that binds transactivation responsive RNA with high affinity.

Alcohols immobilization onto 2-chlorotritylchloride resin under microwave irradiation

The immobilization of alcohols onto 2-chlorotritylchloride resin using microwave irradiation was studied. Three different Fmoc-aminoalcohols were tested: the phenol-like Fmoc-tyramine, the primary alcohol Fmoc-ethanolamine, and the secondary alcohol Fmoc-

Preparation method of triphosphate compound and deoxynucleotide

The invention discloses a preparation method of a triphosphate compound and deoxynucleotide. In the preparation method of the triphosphate compound, tetrahydrofuran is used for replacing trimethyl phosphate/triethyl phosphate, tri-n-propylamine is used for replacing tri-n-butylamine, and acetonitrile is used for replacing N,N-dimethylformamide; so that the preparation method has the advantages that the yield is high, few byproducts are produced, a solvent is easy to remove, and the triphosphate compound is non-toxic, safe and the like. According to the preparation method of the deoxynucleotide, the morpholine dimethylformamide solution is used for replacing a triethylamine solution to remove the F-moc group, so that the reaction time is greatly shortened, the generation of byproducts is reduced, and the yield is improved.

Method for stereoselective preparation of beta type single/double artemisinin (symmetric and asymmetric) alkyl ether amine maleate

The invention relates to the field of organic synthesis and pharmaceutical intermediates, particularly to a method for stereoselective preparation of beta type single/double artemisinin (symmetric andasymmetric) alkyl ether amine maleate. The method compr

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Fast and Facile Synthesis of 4-Nitrophenyl 2-Azidoethylcarbamate Derivatives from N-Fmoc-Protected α-Amino Acids as Activated Building Blocks for Urea Moiety-Containing Compound Library

A fast and facile synthesis of a series of 4-nitrophenyl 2-azidoethylcarbamate derivatives as activated urea building blocks was developed. The N-Fmoc-protected 2-aminoethyl mesylates derived from various commercially available N-Fmoc-protected α-amino ac

ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS

The disclosure relates to compositions comprising a HBV RNAi agent. In some embodiments, the HBV RNAi agent comprises a sense and an anti-sense strand, each strand being an 18-mer and the strands together forming a blunt-ended duplex, wherein the 3′ end of at least one strand terminates in a phosphate or modified internucleoside linker and further comprises, in 5′ to 3′ order: a spacer; a second phosphate or modified internucleoside linker; and a 3′ end cap. In some embodiments, the 3′ end of both the sense and anti-sense strand further comprise, in 5′ to 3′ order: a spacer; a second phosphate or modified internucleoside linker; and a 3′ end cap. The two strands can have the same or different spacers, phosphates or modified internucleoside linkers, and/or 3′ end caps. The strands can be ribonucleotides, or, optionally, one or more nucleotide can be modified or substituted. Optionally, at least one nucleotide comprises a modified internucleoside linker. Optionally, the RNAi agent can be modified on one or both 5′ end. Optionally, the sense strand can comprise a 5′ end cap which reduces the amount of the RNA interference mediated by this strand. Optionally, the RNAi agent is attached to a ligand. This format can be used to devise RNAi agents to a variety of different targets and sequences. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference. The disclosure also pertains to methods of treating, ameliorating and preventing HBV in a patient involving the step of administering to the patient a therapeutic amount of a HBV RNAi agent.